Peak6 Investments LLC Argenx Se Call Options Transaction History

Peak6 Investments LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	BUY	$434.22 - $551.9 $2.56 Million - $3.26 Million	5,900 New	5,900 $3.2 Million
Q1 2024 May 14, 2024	SELL	$356.95 - $413.29 $535,425 - $619,935	-1,500 Reduced 46.88%	1,700 $669,000
Q4 2023 Feb 13, 2024	SELL	$338.91 - $506.01 $813,384 - $1.21 Million	-2,400 Reduced 42.86%	3,200 $1.22 Million
Q3 2023 Nov 13, 2023	BUY	$369.35 - $548.43 $1.7 Million - $2.52 Million	4,600 Added 460.0%	5,600 $2.75 Million
Q2 2023 Aug 11, 2023	SELL	$360.14 - $422.58 $540,210 - $633,870	-1,500 Reduced 60.0%	1,000 $389,000
Q1 2023 May 12, 2023	BUY	$334.23 - $403.65 $835,575 - $1.01 Million	2,500 New	2,500 $931,000
Q1 2020 May 14, 2020	SELL	$108.83 - $165.23 $304,724 - $462,644	-2,800 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$106.59 - $164.21 $298,452 - $459,788	2,800 New	2,800 $449,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Peak6 Investments LLC with notifications on news.